(Jinan, China, and Princeton, NJ) KBP BioSciences, a clinical stage biopharma company announced today that it will present Phase I/II clinical date on KBP-5074 during the annual meeting of the American Society of Nephrology (ASN) to be held in Chicago on Nov 15-20. KBP will deliver the following presentations:
- “Pharmacokinetics and Safety of KBP-5074 in Phase 1 Single and Multiple Ascending Dose Studies”(PosterSA-PO504)
- “Safety, Tolerability and Pharmacokinetics of KBP-5074 in Patients withMild-to-Moderate Chronic Kidney Disease: A Randomized, Open-LabelStudy” (PUB116)
KBP-5074 is a non-steroidal mineralocorticoid receptor antagonist (MRA). Clinical studies have demonstrated that MRAs have therapeutic effects on chronic kidney disease (CKD), hypertension and heart failure. However, marketed MRAs cause serious side effects of hyperkalemia, which can lead to arrhythmia and cardiac arrest. These MRAs are not suitable for CKD patients with various cardiovascular co-morbidities. Globally over 100 million patients suffering these ailments are left with no effective treatments. Phase IIa trials showed that KBP-5074 has highly promising hyperkalemia profile, making it the best hope for CKD patients as well as CKD patients with hypertension and heart failure co-morbidities.